Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines

Abstract

The over-expression of c-erbB-2/ HER-2, a receptor tyrosine kinase, correlates with poor prognosis in patients with breast and ovarian cancer. In the human breast cancer cell line, MDA-MB-435, c-erbB-2 over-expression results in increased chemoinvasion and higher metastatic properties in nude mice. However, the mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear. We have determined that over-expression of c-erbB-2 in MDA-MB-435 cells, and in some additional breast cancer cell lines, is associated with graphic increases in mRNA and protein levels of the actin bundling protein fascin. Heightened fascin expression has been observed in other systems to result in greatly increased cell motility, and indeed, our work employing semi-automated time-lapse microscopy demonstrates that MDA-MB-435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics and locomotion, while visualization of bundled microfilaments within fixed cells revealed enhanced formation of dendritic-like processes, microspikes and other dynamic actin based structures. To address the means by which c-erbB-2 over-expression might result in elevated fascin levels, we identified multiple perfect match TCF and NF-κB consensus sites in fascin’s promoter and first intron, which appeared consistent with the greater endogenous transcriptional activities of TCF and NF-κB in c-erbB-2 over-expressing MDA-MB-435 cells. While such transcriptional modulation may occur in the context of the intact gene/chromatin, subsequent tests using reporter constructs did not support involvement of these signaling pathways. In conclusion, highly increased fascin levels were observed in MDA-MB-435 over-expressing c-erbB-2, likely contributing to these cells’ altered actin dynamics, and increased cell motility and malignancy. Studies in progress aim to discern the means by which c-erbB-2 over-expression leads to transcriptional activation of the fascin gene.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J and Kumar R. . 1998 J. Biol. Chem. 273: 28238–28246.

  • Adams JC, Clelland JD, Collett GD, Matsumura F, Yamashiro S and Zhang L. . 1999 Mol. Biol. Cell. 10: 4177–4190.

  • Aljada A, Ghanim H, Assian E, Mohanty P, Hamouda W, Garg R and Dandona P. . 1999 J. Clin. Endocrinol Metab. 84: 3386–3389.

  • Behrens J. . 1999 Cancer Metastasis Rev. 18: 15–30.

  • Cailleau R, Young R, Olive M and Reeves W. . 1974 J. Natl. Cancer Inst. 53: 661–674.

  • Cano RJ, Torres MJ, Klem RE and Palomares JC. . 1992 Biotechniques 12: 264–269.

  • Caron de Fromentel C, Nardeux PC, Soussi T, Lavialle C, Estrade S, Carloni G, Chandrasekaran K and Cassingena R. . 1985 Exp. Cell. Res. 160: 83–94.

  • Crowell PL, Chang RR, Ren ZB, Elson CE and Gould MN. . 1991 J. Biol. Chem. 266: 17679–17685.

  • De Corte V, De Potter C, Vandenberghe D, Van Laerebeke N, Azam M, Roels H, Mareel M and Vandekerckhove J. . 1994 J. Cell. Sci. 107: 405–416.

  • del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C and Lacal JC. . 1997 Oncogene 15: 3047–3057.

  • Dhaliwal MK, Giovanella BC and Pathak S. . 1990 Anticancer Res. 10: 113–117.

  • Dickason RR, Edwards RA, Bryan J and Huston DP. . 1995 J. Immunol. Methods 185: 237–244.

  • Eastman Q and Grosschedl R. . 1999 Curr. Opin. Cell. Biol. 11: 233–240.

  • Edwards RA and Bryan J. . 1995 Cell. Motil. Cytoskeleton 32: 1–9.

  • Edwards RA, Herrera-Sosa H, Otto J and Bryan J. . 1995 J. Biol. Chem. 270: 10764–10770.

  • Eliopoulos AG and Young LS. . 1998 Oncogene 16: 1731–1742.

  • Fazioli F, Kim UH, Rhee SG, Molloy CJ, Segatto O and Di Fiore PP. . 1991 Mol. Cell. Biol. 11: 2040–2048.

  • Gaffney EV. . 1982 Cell. Tissue Res. 227: 563–568.

  • Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE and Oliff A. . 1993 J. Biol. Chem. 268: 7617–7620.

  • Grothey A, Hashizume R, Sahin AA and McCrea PD. . 2000 Br. J. Cancer 88.

  • Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ. . 1992 Proc. Natl. Acad. Sci. USA 89: 10578–10582.

  • Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LCJM and Collard JG. . 1997 Science 278: 1464–1466.

  • Hung MC and Lau YK. . 1999 Semin. Oncol. 26: 51–59.

  • Keely PJ, Westwick JK, Whitehead IP, Der CJ and Parise LV. . 1997 Nature 390: 632–636.

  • Klapper LN, Kirschbaum MH, Sela M and Yarden Y. . 2000 Adv. Cancer Res. 77: 25–79.

  • Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H. . 1997 Science 275: 1784–1787.

  • Kzhyshkowska JG, Kiselev AV, Gordina GA, Kurmashow VI, Portjanko NM, Ostashkin AS and Ilyin KV. . 1996 Immunol. Lett. 53: 101–104.

  • McCrea PD, Brieher WM and Gumbiner BM. . 1993 J. Cell. Biol. 123: 477–484.

  • McCrea PD, Turck CW and Gumbiner B. . 1991 Science 254: 1359–1361.

  • Mitchison TJ and Cramer LP. . 1996 Cell. 84: 371–379.

  • Montross WT, Ji H and McCrea PD. . 2000 J. Cell. Sci. 113: 1759–1770.

  • Mosialos G, Yamashiro S, Baughman RW, Matsudaira P, Vara L, Matsumura F, Kieff E and Birkenbach M. . 1994 J. Virol. 68: 7320–7328.

  • Muller WJ, Sinn E, Pattengale PK, Wallace R and Leder P. . 1988 Cell. 54: 105–115.

  • Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T and Hirohashi S. . 1994 Biochem. Biophys. Res. Commun. 205: 73–78.

  • Peles E, Lamprecht R, Ben-Levy R, Tzahar E and Yarden Y. . 1992 J. Biol. Chem. 267: 12266–12274.

  • Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mosialos G and Said JW. . 1997 Am. J. Pathol. 150: 543–562.

  • Reddy SA, Huang JH and Liao WS. . 2000 J. Immunol. 164: 1355–1363.

  • Reese DM and Slamon DJ. . 1997 Stem. Cells. 15: 1–8.

  • Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T and Pelicci PG. . 1993 Oncogene 8: 2105–2112.

  • Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N, Machinami R and Hirohashi S. . 1996 Oncogene 13: 883–889.

  • Tan M, Grijalva R and Yu D. . 1999 Cancer Res. 59: 1620–1625.

  • Tan M, Yao J and Yu D. . 1997 Cancer Res. 57: 1199–1205.

  • Tao YS, Edwards RA, Tubb B, Wang S, Bryan J and McCrea PD. . 1996 J. Cell. Biol. 134: 1271–1281.

  • Tilney LG, Connelly PS, Vranich KA, Shaw MK and Guild GM. . 1998 J. Cell. Biol. 143: 121–133.

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM. . 1996 Science 274: 787–789.

  • Vlahos CJ, Matter WF, Hui KY and Brown RF. . 1994 J. Biol. Chem. 269: 5241–5248.

  • Wong V, Ching D, McCrea PD and Firestone GL. . 1999 J. Biol. Chem. 274: 5443–5453.

  • Yamashiro S, Yamakita Y, Ono S and Matsumura F. . 1998 9: 993–1006.

  • Yost C, Torres M, Miller JR, Huang E, Kimelman D and Moon RT. . 1996 Genes. Dev. 10: 1443–1454.

  • Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL and Hung MC. . 1994 Cancer Res. 54: 3260–3266.

  • Yu DH and Hung MC. . 1991 Oncogene 6: 1991–1996.

Download references

Acknowledgements

Axel Grothey was supported by a grant of the German Cancer Foundation (Mildred-Scheel-Stiftung). We also gratefully acknowledge the current and past sources of support that have contributed to the execution of this work: NIH RO1 Grant GM 52112; Texas ARP Grant 15–135; March of Dimes Basil O’Connor Grant 5-0926; Kleberg Foundation Award; and CCSG Developmental Funds CCSG-CA 16672.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grothey, A., Hashizume, R., Ji, H. et al. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19, 4864–4875 (2000). https://doi.org/10.1038/sj.onc.1203838

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203838

Keywords

This article is cited by

Search

Quick links